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Abstract
Introduction Endocrine therapy is the most important treatment
option for women with hormone receptor-positive breast cancer.
The potential mechanisms for endocrine resistance involve
estrogen receptor (ER)-coregulatory proteins and cross-talk
between ER and other growth factor-signaling networks.
However, the factors and pathways responsible for endocrine
resistance are still poorly identified.
Materials and methods The expression of HER2, p53, and
Ki67 was examined by immunohistochemistry in primary breast
tumour specimens from 73 metastatic breast cancer patients
who received first-line treatment with endocrine therapy on
relapse, and analysed to determine whether expression of these
molecular markers affected the response to endocrine therapy.
Results Of the 73 invasive ductal carcinomas, 12.3%, 21.9%,
and 35.6% were positive for HER2 overexpression, p53 protein
accumulation, and Ki67 expression, respectively. All patients
received endocrine therapy as first-line treatment for metastatic
breast cancer; 34 patients (46.6%) responded. Patients with
primary breast tumours that had p53 protein accumulation and
Ki67 expression showed significantly more resistance to
endocrine therapy (P = 0.0049 and P = 0.024, respectively).
There were also tendencies for HER2 overexpression to
correlate with resistance to endocrine therapy, but this did not
reach significance. p53 protein accumulation and HER2
overexpression significantly reduced post-relapse survival (P <
0.0001 and P = 0.001, respectively), and these factors were
also statistically significant in a multivariate analysis.
Conclusion These data suggest that p53 protein accumulation
is helpful in selecting patients who may benefit from endocrine
therapy and is a prognostic marker in hormone receptor-positive
metastatic breast cancer.
Introduction
Endocrine therapy has become the most important treatment
option for women with estrogen receptor (ER)-positive breast
cancer. Nevertheless, many breast cancer patients with
tumours expressing high levels of ER are unresponsive to
endocrine therapy, and all patients with advanced disease
eventually develop resistance to the therapy. The potential
mechanisms behind either intrinsic or acquired endocrine
resistance involve ER-coregulatory proteins and cross-talk
between the ER pathway and other growth factor-signaling
networks [1,2]. An understanding of the molecular mecha-
nisms that modulate the activity of the estrogen-signaling net-
work has enabled new ways of overcoming endocrine
resistance to be developed.
Several specific proteins have been suggested to contribute
to endocrine therapy resistance. HER2 overexpression might
be associated with reduced efficacy of adjuvant endocrine
therapy with tamoxifen [3-5]. De Laurentiis and colleagues
recently conducted a meta-analysis and found that HER2-pos-
itive metastatic breast cancer was less responsive to any type
of endocrine therapy [6].
Nearly one third of breast tumours have mutations in the p53
gene, which are associated with high histological grade and
rapid progression [7]. Immunohistochemical assays generally
detect nuclear accumulation of the protein, which is often
related to conformational alterations and a prolonged half-life
of the encoded protein [8,9]. Mutation of the p53 gene or over-
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expression of its protein product has been identified in 14% to
52% of primary breast tumour specimens, and these altera-
tions were found to be associated with poor prognosis in an
analysis of more than 3,000 patients with primary breast can-
cer [10]. We recently analysed the expression of HER2, p53,
and Ki67 in 506 invasive ductal carcinoma tissues and
showed that the coexistence of HER2 overexpression and
p53 protein accumulation was a strong prognostic molecular
marker in breast cancer [11].
Apoptosis may represent a common mechanism whereby a
variety of antitumour treatments results in cell death. Cells with
loss of p53 gene function may be unable to undergo apoptosis
and thus be resistant to these forms of therapy [12]. Because
mutated protein might accumulate in cells, immunohistochem-
ical staining has been a popular surrogate marker for p53
mutational status. Studies have been published that examined
the predictive value of p53 alterations at the gene level, or p53
expression status by immunohistochemistry (IHC), for
response to chemotherapy. Many of these studies reported
that p53 alterations predict resistance to anthracyclins [13-
19]; cyclophosphamide, methotrexate, and fluorouracil (CMF);
or other agents [20-22]. However, of the few studies that have
examined the association between p53 status and response
to endocrine therapy [23-27], one study [27] reported a value
for p53 in predicting endocrine resistance.
We previously described that expression of ER-α and proges-
terone receptor (PR) by IHC in primary breast tumours is pre-
dictive of response to endocrine therapy in patients with
metastatic breast cancer who received endocrine therapy on
relapse [28]. In this study, we examined the expression of
HER2, p53, and Ki67 by IHC in primary breast tumour speci-
mens from 73 patients with metastatic breast cancer who
received first-line treatment with endocrine therapy on relapse,
and analysed whether expression of these molecular markers
affected the response to endocrine therapy.
Materials and methods
Patients and breast cancer tissues
Breast tumour specimens from 73 female patients with meta-
static breast cancer, who were treated at Nagoya City Univer-
sity Hospital (Nagoya, Japan) between 1982 and 2002, were
included in this study (Table 1). The study protocol was
approved by the institutional review board and conformed with
the guidelines of the 1975 Declaration of Helsinki. All patients
had undergone surgical treatment for primary breast cancer
(either mastectomy or lumpectomy), and all primary tumours
were ER- or PR-positive. After surgery, five patients (6.9%)
received no additional therapy. Of the remaining 68 patients,
32 (43.8%) received systemic adjuvant therapy consisting of
endocrine therapy (tamoxifen) alone, two (2.7%) received
chemotherapy alone, and 34 (46.6%) received combined
Table 1
Clinicopathological characteristics of patients, primary breast tumours, and treatment
Number of patients (percentage)
Total number of patients 73
Age at diagnosis (years) ≤50
>50
34 (46.6)
39 (53.4)
Range 29 to 77
Tumour size (cm) <2.0
≥2.0
20 (27.4)
53 (72.6)
Number of positive lymph nodes 0
1–3
>3
21 (28.8)
20 (27.4)
32 (43.8)
Histological grade 1
2
3
12 (16.4)
42 (57.5)
19 (26.1)
Adjuvant therapy None
Endocrine therapy
Chemotherapy
Combined
5 (6.9)
32 (43.8)
2 (2.7)
34 (46.6)
Disease-free interval (months) Mean ± SD
Median
39.8 ± 25.7
38
Range 2 to 123
First-line endocrine therapy for metastatic 
breast cancer
Tamoxifen
Aromatase inhibitors
LHRH agonist
LHRH agonist + tamoxifen
Fulvestrant
56 (76.7)
9 (12.3)
3 (4.1)
4 (5.5)
1 (1.4)
LHRH, luteinising hormone-releasing hormone; SD, standard deviation.Available online http://breast-cancer-research.com/content/8/4/R48
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endocrine therapy and chemotherapy. Patients who were pos-
itive for axillary lymph node metastases received either oral
administration of 5-fluorouracil derivatives for 2 years or a
combination of cyclophosphamide, methotrexate, and fluorou-
racil (CMF). Patients were observed for disease recurrence at
least once every 6 months for the first 5 years after the surgery
and thereafter once every year.
First-line endocrine therapy for metastatic breast cancer 
and response criteria
When the patients relapsed and were diagnosed with meta-
static breast cancer, they started endocrine therapy (Table 1).
Patients were assessed monthly for clinical response, which
was defined according to World Health Organization criteria
as complete response, partial response, no change, and pro-
gressive disease. The presence of progressive disease indi-
cated treatment failure; all other clinical responses were
considered to show efficacy of treatment. Stable disease was
included as a response to treatment because patients with
stable disease clearly benefited clinically in metastatic breast
cancer.
Immunohistochemical analysis for ER-α, PR, HER2, p53, 
and Ki67
One 4-µm section of each submitted paraffin block was first
stained with hematoxylin and eosin to verify that an adequate
number of invasive ductal carcinoma cells were present, and
the fixation quality was sufficient for immunohistochemical
analysis as described previously [11,28]. Serial sections (4-
µm) were prepared from selected blocks and float-mounted on
adhesive-coated glass slides for ER-α, PR, HER2, p53, or
Ki67 staining. Primary antibodies included monoclonal mouse
anti-human ER antibody (1D5; Dako Denmark A/S, Glostrup,
Denmark) at 1:100 dilution for ER-α, monoclonal mouse anti-
Table 2
Correlation between clinicopathological factors and molecular markers
HER2 P53 Ki67
Positive/total 
(percentage)
P Positive/total 
(percentage)
P Positive/total 
(percentage)
P
Total 9/73 (12.3) 16/73 (21.9) 26/73 (35.6)
Tumour size (cm)
<2.0 4/20 (20.0) 0.41 5/20 (25.0) 0.94 7/20 (35.0) >0.99
≥2.0 5/53 (9.4) 11/53 (20.8) 19/53 (35.8)
Number of positive lymph nodes
0 1/22 (4.5) 0.34 3/22 (12.6) 0.41 6/22 (27.2) 0.47
≥1 8/51 (15.7) 13/51 (25.5) 20/51 (39.2)
Histological grade
1 0/12 (0) 0.36 0/12 (0) 0.05 3/12 (25.0) 0.18
2 6/42 (14.3) 9/42 (21.4) 13/42 (31.0)
3 3/19 (15.8) 7/19 (36.8) 10/19 (52.6)
Estrogen receptor-α
Negative 4/17 (23.5) 0.23 5/17 (29.4) 0.60 8/17 (47.1) 0.40
Positive 5/56 (8.9) 11/56 (19.6) 18/56 (32.1)
Progesterone receptor
Negative 3/18 (16.7) 0.81 5/18 (27.8) 0.71 9/18 (50.0) 0.23
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human PgR antibody (636; Dako Denmark A/S) at 1:100 dilu-
tion for PR, rabbit anti-human c-erbB-2 oncoprotein antibody
(Dako Denmark A/S) at 1:200 dilution for HER2, monoclonal
mouse anti-human p53 protein antibody (PAb1801; Novocas-
tra, Newcastle, UK) at 1:50 dilution for p53, and monoclonal
mouse anti-human Ki67 antibody (MIB-1; Dako Denmark A/S)
at 1:100 dilution for Ki67. The Dako Denmark A/S EnVision
system (Dako Denmark A/S EnVision labeled polymer, peroxi-
dase) was used as the detection system for ER-α, PR, HER2,
and Ki67. The streptavidin-biotin system (SAB-PO kit; Nichirei
Co., Inc., Tokyo, Japan) was used for detection of the bound
antibody of p53.
Immunohistochemical scoring
Immunostained slides were scored after the entire slide was
evaluated by light microscopy. The expression of ER-α and PR
was scored by assigning proportion and intensity scores, in
accordance with the procedure of Allred and colleagues [29].
Any brown nuclear staining in invasive breast epithelium was
counted toward the proportion score. Tumours with a score of
3 or greater were considered to be positive for ER-α and PR
expression. HER2 immunostaining was evaluated by the same
method as the HercepTest (Dako Denmark A/S). To determine
the score of HER2 expression, the membrane staining pattern
Figure 1
Representative immunohistochemical staining of HER2, p53, and Ki67  in invasive ductal carcinoma Representative immunohistochemical staining of HER2, p53, and Ki67 
in invasive ductal carcinoma. (a) Negative staining of HER2. (b) Positive 
staining of HER2. (c) Negative staining of p53. (d) Positive staining of 
p53. (e) Negative staining of Ki67. (f) Positive staining of Ki67.
Figure 2
Post-relapse survival according to HER2 overexpression, p53 protein  accumulation, and Ki67 expression Post-relapse survival according to HER2 overexpression, p53 protein 
accumulation, and Ki67 expression. (a) Post-relapse survival according 
to HER2 overexpression. (b) Post-relapse survival according to p53 
protein accumulation. (c) Post-relapse survival according to Ki67. 
HER2 overexpression and p53 protein accumulation significantly 
reduced post-relapse survival.Available online http://breast-cancer-research.com/content/8/4/R48
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was estimated and scored on a scale of 0 to 3. Tumours with
a score of 3 were considered to be positive for HER2 overex-
pression. The expression status of p53 and Ki67 was
assessed according to the estimated proportion of nuclear
staining of tumour cells that were positively stained as
described previously [11]. Scoring criteria were as follows: for
p53, score of 0 = none; score of 1, <1/10; score of 2, 1/10 to
1/2; and score of 3, >1/2; for Ki67, score of 0 = none; score
of 1, <1/100; score of 2, 1/100 to 1/10; score of 3, 1/10 to
1/2; and score of 4, >1/2. Tumours with a score of 2 or greater
for p53 were considered to be positive for p53 protein accu-
mulation, and tumours with a score of 3 or greater for Ki67
were considered to be positive for Ki67 expression.
Statistical analysis
The χ2 test was used to compare the immunohistochemical
results of molecular markers with clinicopathological charac-
teristics and response to endocrine therapy. Estimation of
post-relapse survival was performed using the Kaplan-Meier
method, and differences between survival curves were
assessed with the log-rank test. Cox's proportional hazards
model was used for univariate and multivariate analyses of
prognostic values.
Results
Correlation between HER2, p53, and Ki67 expression 
and clinicopathological factors
We examined expression of HER2, p53, and Ki67 in primary
invasive breast carcinomas by IHC from 73 patients with met-
astatic breast cancer who received endocrine therapy as first-
line treatment on relapse (Figure 1). The immunohistochemical
status for HER2, p53, and Ki67 was compared among patient
subgroups according to clinicopathological factors. Of the 73
invasive ductal carcinomas, 12.3%, 21.9%, and 35.6% were
positive for HER2 overexpression, p53 protein accumulation,
and Ki67 expression, respectively (Table 2). No association
was found between HER2 overexpression, p53 protein accu-
mulation, or Ki67 expression and clinicopathological factors.
p53 protein accumulation and Ki67 expression in primary 
breast tumours are predictive of endocrine therapy 
resistance in metastatic breast cancer
At relapse, all patients received endocrine therapy as first-line
treatment for metastatic breast cancer; 34 patients (46.6%)
responded. We analysed whether the expression status of
HER2, p53, and Ki67 in the primary breast tumours affected
the response to endocrine therapy in this setting (Table 3).
Patients with primary breast tumours that had p53 protein
accumulation and Ki67 expression were significantly more
likely to exhibit resistance to endocrine therapy (P = 0.0049
and P = 0.024, respectively). Patients with HER2 overexpres-
sion also showed a tendency for greater resistance to endo-
crine therapy (P  = 0.054), but the trend did not reach
statistical significance.
Patients with HER2 overexpression and p53 protein 
accumulation in primary breast tumours had a 
significantly shorter survival after relapse
We analysed whether expression status of HER2, p53, and
Ki67 in the primary breast tumours affected survival after
relapse. The median follow-up period was 77 months (range,
4 to 234 months). HER2 overexpression significantly reduced
post-relapse survival (P = 0.001) (Figure 2a) by log-rank test.
Moreover, patients with p53 protein accumulation had a signif-
icantly shorter post-relapse survival (P < 0.0001) (Figure 2b).
Univariate analysis (Table 4) demonstrated significant associ-
ations between post-relapse survival and HER2 overexpres-
sion (P = 0.0024) and p53 protein accumulation (P = 0.0002)
as well as expression ER-α (P = 0.0009) and PR (P = 0.0012)
expression. On the other hand, Ki67 expression did not affect
post-relapse survival. The status of expressions of ER-α, PR,
HER2, and p53 were selected for the multivariate analysis.
Patients with primary tumours with HER2 overexpression (P =
0.0046) and p53 protein accumulation (P = 0.013) had signif-
icantly reduced post-relapse survival, whereas those with pos-
itive expression of PR had significantly increased post-relapse
survival (P = 0.045) (Table 4). We conclude that HER2 over-
expression and p53 protein accumulation are independent
prognostic factors of post-relapse survival in patients with met-
Table 3
Correlation between immunohistochemical status of HER2, p53, and Ki67 and response to endocrine therapy
HER2 P53 Ki67
Positive/total 
(percentage)
P Positive/total 
(percentage)
P Positive/total 
(percentage)
P
Response to endocrine therapy (n = 73)
Total 9/73 (12.3) 16/73 (21.9) 26/73 (35.6)
Responders 1/34 (2.9) 0.054 2/34 (5.9) 0.0049a 7/34 (20.6) 0.024a
Non-responders 8/39 (20.5) 14/39 (35.9) 19/39 (48.7)
aP < 0.05 is considered significant.Breast Cancer Research    Vol 8 No 4    Yamashita et al.
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astatic breast cancer who received first-line treatment with
endocrine therapy on relapse.
Discussion
The present study indicates that p53 protein accumulation
predicts resistance to endocrine therapy and decreased post-
relapse survival in patients with metastatic breast cancer who
received first-line treatment with endocrine therapy on relapse.
Experimental data suggest a complex cross-talk between
HER2 and ER, and it has been hypothesised that HER2-posi-
tive tumours may be less responsive to certain endocrine treat-
ments. However, it has yet to be established whether HER2
overexpression is predictive of resistance to endocrine ther-
apy, whether used as an adjuvant therapy after excision of
localised breast cancer or as treatment for metastatic disease.
In the metastatic setting, several groups have identified a cor-
relation between HER2 overexpression and a lower response
rate to endocrine therapy, whereas others have not. De Lau-
rentiis and colleagues recently conducted a meta-analysis of
the published studies to obtain an overall pooled estimate of
the association between HER2 overexpression and treatment
failure rate [6]. They found that HER2-positive metastatic
breast cancer was less responsive to any type of endocrine
therapy. Our data failed to show an association between
HER2 overexpression and resistance to endocrine therapy,
possibly due to the small number of patients in our study. Nev-
ertheless, HER2 overexpression significantly reduced post-
relapse survival.
It has been reported from three groups of clinical trials that
p53 status by IHC does not predict response to tamoxifen
[23-25]. Elledge et al. found that p53 expression as measured
by IHC was not associated with response to tamoxifen in 205
patients with metastatic breast cancer, although patients with
higher p53 had a worse survival [25]. It has also been reported
not to predict tamoxifen resistance in ER-positive, node-posi-
tive breast cancer [24] or in high-risk postmenopausal breast
cancer [23] in adjuvant studies. In contrast, Berns et al. found
that in 401 patients with metastatic breast cancer, p53
expression as measured by enzyme immunoassay of cytoplas-
mic extracts from primary tumours was a predictor of tamoxifen
resistance [27]. Our results indicate that p53 protein accumu-
lation by IHC was predictive of endocrine therapy resistance
and decreased post-relapse survival in metastatic breast can-
cer. The antibody for p53 that Elledge et al. [25] used was also
used in our study. Their results may have differed from ours
because not only tamoxifen, but also aromatase inhibitors and/
or LHRH (luteinising hormone-releasing hormone) agonists,
were used as endocrine therapy in our study. Further studies
to analyse the correlation between response to each endo-
crine therapy agent and p53 status are necessary to under-
stand the role of p53 in endocrine therapy resistance.
Moreover, the conflicting results may be caused by the differ-
ent evaluation methods of p53 status. Geisler et al. demon-
strated that nearly 30% of all mutations in primary breast
cancer, in particular those of the nonsense type, are not
detected by IHC and that most studies evaluating p53 status
by IHC have failed to show a predictive value of p53 for chem-
otherapy, whereas studies evaluating p53 status by DNA
sequencing have reported mutations that predict resistance to
chemotherapy [15]. Therefore, mutational analysis of p53
might be helpful in evaluating the association between p53
status and endocrine therapy resistance.
Conclusion
The present study indicates that p53 protein accumulation
predicts resistance to endocrine therapy and decreased post-
relapse survival in patients with metastatic breast cancer who
received first-line treatment with endocrine therapy on relapse.
Table 4
Prognostic factors in 73 invasive ductal carcinomas compared with post-relapse survival
Univariate Multivariate
P RR 95% CI P RR 95% CI
Age 0.67 0.882 0.494–1.576
Tumour size 0.21 1.483 0.797–2.759
Lymph node 
status
0.40 0.746 0.376–1.479
Histological grade 0.15 0.500 0.197–1.271
ER-α 0.0009a 0.342 0.181–0.645 0.79 1.174 0.354–3.886
PR 0.0012a 0.358 0.192–0.668 0.045a 0.291 0.087–0.972
HER2 0.0024a 3.637 1.582–8.362 0.0046a 3.710 1.498–9.191
p53 0.0002a 3.371 1.765–6.440 0.013a 2.364 1.198–4.665
Ki67 0.16 1.539 0.849–2.790
aP < 0.05 is considered significant. CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; RR, relative risk.Available online http://breast-cancer-research.com/content/8/4/R48
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Our data suggest that p53 protein accumulation is helpful in
selecting patients who may benefit from endocrine therapy
and is a prognostic marker in metastatic breast cancer.
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